Literature DB >> 14688050

Trends in the treatment of orthopaedic prosthetic infections.

Louis Bernard1, Pierre Hoffmeyer, Mathieu Assal, Pierre Vaudaux, Jacques Schrenzel, Daniel Lew.   

Abstract

The most commonly used therapy for prosthetic joint infection is a two-stage prosthetic exchange separated by 6 weeks of intravenous antibiotic therapy. This often results in long periods of hospitalization, morbidity, severe functional impairment and sometimes increased mortality. Therefore novel and challenging therapeutic approaches have been attempted, particularly in hip prosthetic infection. This includes, whenever possible, according to the type of microorganism, antibacterial susceptibility and clinical presentation (including age and comorbidities): (i) less aggressive surgical techniques (debridement and prosthesis retention, or re-implantation with a single-stage exchange arthroplasty); and (ii) antibiotic combinations active against biofilm-associated bacteria, including rifampicin (particularly with quinolones) with excellent bio-availability which allow prolonged and efficient oral therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14688050     DOI: 10.1093/jac/dkh033

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  20 in total

1.  Successful treatment of a prosthetic joint infection due to Mycobacterium abscessus.

Authors:  Andrew Petrosoniak; Paul Kim; Marc Desjardins; B Craig Lee
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

2.  Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.

Authors:  Pierre Vaudaux; Asllan Gjinovci; Manuela Bento; Dongmei Li; Jacques Schrenzel; Daniel P Lew
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

Review 3.  [Revision strategy for periprosthetic infection].

Authors:  B Lehner; D Witte; A J Suda; S Weiss
Journal:  Orthopade       Date:  2009-08       Impact factor: 1.087

4.  PCR diagnostic system in the treatment of prosthetic joint infections.

Authors:  D Jahoda; I Landor; J Benedík; D Pokorný; T Judl; V Barták; I Jahodová; P Fulín; M Síbek
Journal:  Folia Microbiol (Praha)       Date:  2014-12-19       Impact factor: 2.099

5.  Clinical and epidemiological differences between implant-associated and implant-free orthopaedic infections.

Authors:  Céline Cuérel; Sophie Abrassart; Julien Billières; Diego Andrey; Domizio Suva; Victor Dubois-Ferrière; Ilker Uçkay
Journal:  Eur J Orthop Surg Traumatol       Date:  2016-11-14

6.  Designer Dual Therapy Nanolayered Implant Coatings Eradicate Biofilms and Accelerate Bone Tissue Repair.

Authors:  Jouha Min; Ki Young Choi; Erik C Dreaden; Robert F Padera; Richard D Braatz; Myron Spector; Paula T Hammond
Journal:  ACS Nano       Date:  2016-03-02       Impact factor: 15.881

7.  Wound conditioning by vacuum assisted closure (V.A.C.) in postoperative infections after dorsal spine surgery.

Authors:  Ludwig Labler; Marius Keel; Otmar Trentz; Michael Heinzelmann
Journal:  Eur Spine J       Date:  2006-07-12       Impact factor: 3.134

8.  Adverse effects of parenteral antimicrobial therapy for chronic bone infections.

Authors:  C Pulcini; T Couadau; E Bernard; A Lorthat-Jacob; T Bauer; E Cua; V Mondain; R-M Chichmanian; P Dellamonica; P-M Roger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-09-26       Impact factor: 3.267

9.  Specific distribution within the Enterobacter cloacae complex of strains isolated from infected orthopedic implants.

Authors:  Philippe C Morand; Annick Billoet; Martin Rottman; Valérie Sivadon-Tardy; Luc Eyrolle; Luc Jeanne; Asmaa Tazi; Philippe Anract; Jean-Pierre Courpied; Claire Poyart; Valérie Dumaine
Journal:  J Clin Microbiol       Date:  2009-06-10       Impact factor: 5.948

10.  [Preservation of hip prosthesis with local surgical revision and creation of a fistula persistens : an option for palliative treatment of periprosthetic infection in old, polymorbid patients?].

Authors:  A H Tiemann; L Homagk; M Diefenbeck; T Mückley; G O Hofmann
Journal:  Unfallchirurg       Date:  2007-12       Impact factor: 1.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.